- Home
- LUCD vs ANIK Comparison
LUCD vs ANIK Comparison
Compare LUCD & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | ANIK |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 134.8M |
| IPO Year | 2021 | 1993 |
Fundamental Metrics
Financial Performance| Metric | LUCD | ANIK |
|---|---|---|
| Price | $1.20 | $9.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $3.94 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 599.8K | 154.0K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,399,000.00 | ★ $112,806,000.00 |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $147.43 | $4.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.01 | ★ 30.55 |
| 52 Week Low | $0.80 | $7.87 |
| 52 Week High | $1.80 | $18.37 |
Technical Indicators
Market Signals| Indicator | LUCD | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 49.43 |
| Support Level | $1.12 | $9.31 |
| Resistance Level | $1.24 | $9.85 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 78.09 | 43.12 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.